177 related articles for article (PubMed ID: 11145893)
61. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.
Lifson JD; Rossio JL; Arnaout R; Li L; Parks TL; Schneider DK; Kiser RF; Coalter VJ; Walsh G; Imming RJ; Fisher B; Flynn BM; Bischofberger N; Piatak M; Hirsch VM; Nowak MA; Wodarz D
J Virol; 2000 Mar; 74(6):2584-93. PubMed ID: 10684272
[TBL] [Abstract][Full Text] [Related]
62. Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG.
Shen Y; Shen L; Sehgal P; Zhou D; Simon M; Miller M; Enimi EA; Henckler B; Chalifoux L; Sehgal N; Gastron M; Letvin NL; Chen ZW
J Virol; 2001 Sep; 75(18):8690-6. PubMed ID: 11507214
[TBL] [Abstract][Full Text] [Related]
63. Preventing AIDS but not HIV-1 infection with a DNA vaccine.
Shen X; Siliciano RF
Science; 2000 Oct; 290(5491):463-5. PubMed ID: 11183769
[TBL] [Abstract][Full Text] [Related]
64. Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy.
Cervasi B; Paiardini M; Serafini S; Fraternale A; Menotta M; Engram J; Lawson B; Staprans SI; Piedimonte G; Perno CF; Silvestri G; Magnani M
J Virol; 2006 Nov; 80(21):10335-45. PubMed ID: 17041214
[TBL] [Abstract][Full Text] [Related]
65. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys.
Barouch DH; Fu TM; Montefiori DC; Lewis MG; Shiver JW; Letvin NL
Immunol Lett; 2001 Nov; 79(1-2):57-61. PubMed ID: 11595290
[TBL] [Abstract][Full Text] [Related]
66. Cellular gene expression profiles in rhesus macaques challenged mucosally with a pathogenic R5 tropic simian human immunodeficiency virus isolate.
Chung HK; Pise-Masison CA; Radonovich MF; Brady J; Lee JK; Cheon SY; Markham P; Cristillo A; Pal R
Viral Immunol; 2008 Dec; 21(4):411-23. PubMed ID: 19115930
[TBL] [Abstract][Full Text] [Related]
67. Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques.
Trunova N; Tsai L; Tung S; Schneider E; Harouse J; Gettie A; Simon V; Blanchard J; Cheng-Mayer C
Virology; 2006 Aug; 352(1):169-77. PubMed ID: 16730772
[TBL] [Abstract][Full Text] [Related]
68. Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?
Bucy RP; Kilby JM
AIDS; 2001 Feb; 15 Suppl 2():S36-42. PubMed ID: 11424975
[TBL] [Abstract][Full Text] [Related]
69. Cellular immune response to SIVmac and HIV-2 in macaques: model for the human HIV-1 infection.
Voss G; Hunsmann G
J Acquir Immune Defic Syndr (1988); 1993 Sep; 6(9):969-76. PubMed ID: 8340900
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of antiretrovirals in animal models of HIV infection.
Van Rompay KK
Antiviral Res; 2010 Jan; 85(1):159-75. PubMed ID: 19622373
[TBL] [Abstract][Full Text] [Related]
71. Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
Tsai CC; Emau P; Sun JC; Beck TW; Tran CA; Follis KE; Bischofberger N; Morton WR
J Med Primatol; 2000 Aug; 29(3-4):248-58. PubMed ID: 11085587
[TBL] [Abstract][Full Text] [Related]
72. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.
Nowak MA; Lloyd AL; Vasquez GM; Wiltrout TA; Wahl LM; Bischofberger N; Williams J; Kinter A; Fauci AS; Hirsch VM; Lifson JD
J Virol; 1997 Oct; 71(10):7518-25. PubMed ID: 9311831
[TBL] [Abstract][Full Text] [Related]
73. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques.
Tsai CC; Follis KE; Beck TW; Sabo A; Bischofberger N; Dailey PJ
AIDS Res Hum Retroviruses; 1997 May; 13(8):707-12. PubMed ID: 9168239
[TBL] [Abstract][Full Text] [Related]
74. PMPA beats SIV again.
GMHC Treat Issues; 1996 May; 10(5):8-9. PubMed ID: 11363586
[TBL] [Abstract][Full Text] [Related]
75. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
Deeks SG; Barditch-Crovo P; Lietman PS; Hwang F; Cundy KC; Rooney JF; Hellmann NS; Safrin S; Kahn JO
Antimicrob Agents Chemother; 1998 Sep; 42(9):2380-4. PubMed ID: 9736567
[TBL] [Abstract][Full Text] [Related]
76. CD4(+) T helper cells and the role they play in viral control.
Norris PJ; Rosenberg ES
J Mol Med (Berl); 2002 Jul; 80(7):397-405. PubMed ID: 12110945
[TBL] [Abstract][Full Text] [Related]
77. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes.
Dis Markers; 1990; 8(1):37-8. PubMed ID: 2155735
[No Abstract] [Full Text] [Related]
78. Early treatment with 9-(2-phosphonylmethoxyethyl)adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques.
Joag SV; Li Z; Foresman L; Pinson DM; Stephens EB; Raghavan R; Navé JF; Casara P; Narayan O
AIDS Res Hum Retroviruses; 1997 Feb; 13(3):241-6. PubMed ID: 9115811
[TBL] [Abstract][Full Text] [Related]
79. Prevention of murine AIDS development by (R)-9-(2-phosphonylmethoxypropyl)adenine.
Suruga Y; Makino M; Okada Y; Tanaka H; De Clercq E; Baba M
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):316-22. PubMed ID: 9704936
[TBL] [Abstract][Full Text] [Related]
80. In vivo CD8+ T cell control of immunodeficiency virus infection in humans and macaques.
Asquith B; McLean AR
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6365-70. PubMed ID: 17404226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
